VC-backed TM3 Therapeutics appoints board chairman
TM3 Therapeutics, a developer of treatments for rare neurodegenerative and metabolic disorders, has named Dr. Peter Van Vlasselaer as chairman of its board of directors. Currently, he is the CEO of ARMO Biosciences. TM3's backers include Sofinnova Partners and INKEF Capital.
29 November 2017•3 mins read
